Intra-CSF rituximab for lymhomatous meningitis.
Chamberlain
Marc C
MC
Glantz
Michael J
MJ
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D005134:Eye Neoplasms / Q000188:drug therapy*; D006801:Humans; D007276:Injections, Intraventricular; D008223:Lymphoma / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab